更多栏目
搜索
China Licensing Deals Tracker: Feb 2021
储旻华·2021-04-04
PharmaDJ
Junshi, Coherus Sign Deal Bringing New Cancer Drug to North America.

China Licensing Deals Tracker: Feb 2021


Writer: Minhua Chu

Editor: Justin Fischer


In spite of the weeklong national holiday of Chinese New Year, drug licensing deals in China showed no signs of slowing down this February. Chinese companies continue to buy overseas assets, recently inking nine in-licensing deals and three out-licensing deals.


gaitubao_1 (1).png


Five of the deals' dollar amounts were publicly disclosed, showing an average value of 228.4 million USD.


gaitubao_4 (1).png


The biggest deal of the month was between Junshi Biosciences (HKEX: 1877; SSE: 688180) and US biosimilar company Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS). Coherus acquired exclusive rights to the development and commercialization of toripalimab, Junshi’s anti-PD-1 antibody, in the United States and Canada.


In return, Coherus will pay up to 1.11 billion USD upfront as well as an exercise fee and milestone payments for granting the toripalimab license and two option programs (if exercised). Additionally, Junshi has also granted Coherus options for JS006 (an anti-TIGIT antibody) and JS018-1 (a next-generation engineered IL-2 cytokine) as well as right of first negotiation on two early-stage checkpoint inhibitor antibodies.  


A rolling submission of the Biologics License Application (BLA) for toripalimab to the US Food and Drug Administration (FDA) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”) was initiated in March.


There is currently an excess of PD-1/PD-L1 monoclonal antibody developers in China, so the competition is fierce. Eight have already been launched, and 54 entered clinical development by the end of January 2021.


Entering new markets like North America and Europe therefore amounts to sound strategy for Junshi. In fact, domestic PD-1 monoclonal antibody developers often go this route. BeiGene and Innovent, for instance, have licensed their products to Novartis and Eli Lilly, respectively.


31.jpeg


Apollomics reached three in-licensing deals in February as well. Incubated by OrbiMed Asia, Apollomics is a biopharmaceutical company specializing in the development of oncology therapies.


Before the deals, nearly all of Apollomics's pipelines were self-developed. The company recently filed a prospectus to the Hong Kong Stock Exchange for an IPO as well.


文章关键字:the US Food and Drug Administration (FDA),Junshi Biosciences,Biologics License Application (BLA),PD-1/PD-L1,TIGIT,NPC,Apollomics,Coherus BioSciences,Inc.
4466
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2020 研发客.All Rights Reserved.
建议反馈: Support@PharmaDJ.com
备案/许可证编号: 沪ICP备17054709号-1
联系电话:021 - 88194359